With recent plans announced by the UK’s prime minister to remain part of the European Medicines Agency (EMA), which would be favourable for many in the pharma industry, I will look at these developments as well as how they will impact industry and the reactions from leaders in the field.
stopwatch
At the beginning of March, the prime minister, Theresa May, spoke about her plans to work with the European Union (EU) on terms that would mean the UK can remain part of the EMA. This announcement was met with guarded positivity from various bodies that represent the pharmaceutical and biotech industries, which have lobbied for cooperation from the initial outcome of the referendum back in 2016.